Hepatic arterial infusion pump chemotherapy combined with systemic chemotherapy for borderline resectable and unresectable colorectal liver metastases: phase II feasibility study

CONCLUSION: HAIP-SYS for borderline resectable and unresectable CRLMs was feasible and safe in the Netherlands. This has led to a successive multicentre phase III randomized trial investigating oncological benefit (EUDRA-CT 2023-506194-35-00). Current trial registration number: clinicaltrials.gov (NCT04552093).PMID:38608150 | DOI:10.1093/bjs/znae089

Source: The British Journal of Surgery - April 12, 2024 Category: Surgery Authors: Myrtle F Krul Niels F M Kok Harun Osmani Florian E Buisman Bas Groot Koerkamp Dirk J Grunhagen Cornelis Verhoef Bianca Mostert Petur Snaebjornsson Bram Westerink Elisabeth G Klompenhouwer Maarten L Donswijk Theo J M Ruers Joeri A J Douma Nico van Blijderv Source Type: research